Published in two articles, the results of a phase II clinical trial indicate that psilocybin-assisted therapy can benefit people with major depression and cancer. The participants of the trial did not only experience fewer depressive symptoms but were also satisfied with the therapy.
Phase II Open-Label Trial of Psilocybin-Assisted Therapy
The phase II open-label trial involved adults suffering from cancer and major depression. There were 30 participants at Sunstone Therapies in Rockville, Maryland. A single dose of 25 mg of psilocybin, along with a therapy session of 1:1, was given.
Lead author Manish Agarwal, MD, explained,
The participants had moderate-to-severe depression. Dr. Agrawal and his colleagues discovered that after eight weeks of treatment, patients’ depression severity scores reduced by an average of 19.1 points, indicating that the majority no longer experienced depression.
Furthermore, 80% of subjects had a sustained response to treatment, with 50% experiencing complete remission of depression symptoms after one week, which lasted for eight weeks. Most treatment-related side effects, such as nausea and headaches, were mild.
He further said,
Dr. Agrawal is also the senior author of another study led by Yvan Beaussant, MD, MSc, of Dana-Farber Cancer Institute, in which the participants had positive experiences.
MEDizzy Journal serves the global medical community with the latest news, medical cases, images, videos, stories, and thought-provoking articles. The collection is curated to provide the most reliable, entertaining, relevant, and valuable content available as it’s published. It’s our mission to bridge gaps between healthcare professionals all over the world, inspiring the advancement of knowledge and education in one of society’s most vital sectors. MEDizzy Journal is founded on the belief that a network of education and insights will help improve patient outcomes and the lives of healthcare workers in every field while accelerating the global advancement of medicine. Members of MEDizzy Journal can receive notifications when new daily content is posted.